“Conjunctivitis Does Not Increase With Longer Duration of Lebrikizumab Exposure in Patients With Moderate-to-Severe Atopic Dermatitis” (2023) SKIN The Journal of Cutaneous Medicine, 7(6), p. s276. doi:10.25251/skin.7.supp.276.